Katharina G. Mcfarland - Nov 20, 2023 Form 4 Insider Report for Transphorm, Inc. (TGAN)

Role
Director
Signature
/s/ Cameron McAulay, Attorney-in-Fact
Stock symbol
TGAN
Transactions as of
Nov 20, 2023
Transactions value $
-$10,580
Form type
4
Date filed
11/21/2023, 04:34 PM
Previous filing
Oct 24, 2023
Next filing
Nov 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TGAN Common Stock Sale -$10.6K -3.52K -3.75% $3.01 90.2K Nov 20, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.
F2 This sale price represents the weighted average sale price of the shares sold ranging from $3.00 to $3.025 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.